These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 26842686)

  • 41. Economic Impact of Oritavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in the Emergency Department or Observation Setting: Cost Savings Associated with Avoidable Hospitalizations.
    Lodise TP; Fan W; Sulham KA
    Clin Ther; 2016 Jan; 38(1):136-48. PubMed ID: 26708118
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vancomycin resistance: are there better glycopeptides coming?
    Linden PK
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):917-28. PubMed ID: 19053904
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.
    Scott LJ
    Drugs; 2015 Jul; 75(11):1281-91. PubMed ID: 26105117
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Improved economic and clinical outcomes with oritavancin versus a comparator group for treatment of acute bacterial skin and skin structure infections in a community hospital.
    Saddler K; Zhang J; Sul J; Patel P; Castro-Lainez M; Stevens ML; Kosler S; Lowery E; Sierra-Hoffman M
    PLoS One; 2021; 16(3):e0248129. PubMed ID: 33735185
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections.
    Brade KD; Rybak JM; Rybak MJ
    Infect Dis Ther; 2016 Mar; 5(1):1-15. PubMed ID: 26831328
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose.
    Fetterly GJ; Ong CM; Bhavnani SM; Loutit JS; Porter SB; Morello LG; Ambrose PG; Nicolau DP
    Antimicrob Agents Chemother; 2005 Jan; 49(1):148-52. PubMed ID: 15616289
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tedizolid: A New Oxazolidinone Antibiotic for Skin and Soft Tissue Infections.
    Chahine EB; Sucher AJ; Knutsen SD
    Consult Pharm; 2015 Jul; 30(7):386-94. PubMed ID: 26173190
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New Gram Positive Agents to Treat Acute Bacterial Skin and Skin Structure Infections.
    Li R; Nailor MD
    Conn Med; 2016 Mar; 80(3):175-80. PubMed ID: 27169303
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Telavancin: a novel lipoglycopeptide antibiotic.
    Charneski L; Patel PN; Sym D
    Ann Pharmacother; 2009 May; 43(5):928-38. PubMed ID: 19401479
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
    Das B; Sarkar C; Biswas R; Pandey S
    Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
    Ramdeen S; Boucher HW
    Expert Opin Pharmacother; 2015; 16(13):2073-81. PubMed ID: 26239321
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin.
    Münch D; Engels I; Müller A; Reder-Christ K; Falkenstein-Paul H; Bierbaum G; Grein F; Bendas G; Sahl HG; Schneider T
    Antimicrob Agents Chemother; 2015 Feb; 59(2):772-81. PubMed ID: 25403671
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oritavancin, a new lipoglycopeptide antibiotic: results from a thorough QT study.
    Darpo B; Lee SK; Moon TE; Sills N; Mason JW
    J Clin Pharmacol; 2010 Aug; 50(8):895-903. PubMed ID: 20484618
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005-2008.
    Arhin FF; Moeck G; Draghi DC; Pillar CM; Sahm DF
    Int J Antimicrob Agents; 2010 Nov; 36(5):474-6. PubMed ID: 20846829
    [No Abstract]   [Full Text] [Related]  

  • 55. Mechanism of action of oritavancin and related glycopeptide antibiotics.
    Allen NE; Nicas TI
    FEMS Microbiol Rev; 2003 Jan; 26(5):511-32. PubMed ID: 12586393
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens.
    Cornaglia G; Rossolini GM
    Clin Microbiol Infect; 2009 Mar; 15(3):218-23. PubMed ID: 19335369
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis.
    Jensen IS; Lodise TP; Fan W; Wu C; Cyr PL; Nicolau DP; DuFour S; Sulham KA
    Clin Drug Investig; 2016 Feb; 36(2):157-68. PubMed ID: 26692006
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review.
    Kmeid J; Kanafani ZA
    Core Evid; 2015; 10():39-47. PubMed ID: 25709561
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans.
    Ambrose PG; Drusano GL; Craig WA
    Clin Infect Dis; 2012 Apr; 54 Suppl 3():S220-8. PubMed ID: 22431852
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections.
    Mitra S; Saeed U; Havlichek DH; Stein GE
    Infect Drug Resist; 2015; 8():189-97. PubMed ID: 26185459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.